Literature DB >> 18990758

Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma.

James R Cerhan1, Wen Liu-Mares, Zachary S Fredericksen, Anne J Novak, Julie M Cunningham, Neil E Kay, Ahmet Dogan, Mark Liebow, Alice H Wang, Timothy G Call, Thomas M Habermann, Stephen M Ansell, Susan L Slager.   

Abstract

Non-Hodgkin's lymphoma (NHL) is a cancer closely associated with immune function, and the tumor necrosis factor (TNF) G-308A promoter polymorphism, which influences immune function and regulation, was recently reported by the InterLymph Consortium to be associated with NHL risk. TNF signaling activates the nuclear factor-kappaB (NF-kappaB) canonical pathway, leading to transcriptional activation of multiple genes that influence inflammation and immune response. We hypothesized that, in addition to TNF signaling, common genetic variation in genes from the NF-kappaB canonical pathway may affect risk of NHL. We genotyped 54 single nucleotide polymorphisms (SNP) within TNF, lymphotoxin A LTA, and nine NF-kappaB genes from the canonical pathway (TNFRSF1A, TRADD, TRAF2, TRAF5, RIPK1, CHUK, IKBKB, NFKB1, and REL) in a clinic-based study of 441 incident cases and 475 frequency-matched controls. Tagging SNPs were selected from HapMap supplemented by putative functional SNPs for LTA/TNF. We used principal components and haplo.stats to model gene-level associations and logistic regression to model SNP-level associations. Compared with the wild-type (GG), the AA genotype for the TNF promoter polymorphism G-308A (rs1800629) was associated with increased risk of NHL [odds ratio (OR), 2.14; 95% confidence interval (95% CI), 0.94-4.85], whereas the GA genotype was not (OR, 1.00; 95% CI, 0.74-1.34). This association was similar for follicular lymphoma and diffuse large B-cell lymphoma. A previously reported LTA/TNF haplotype was also associated with NHL risk. In gene-level analysis of the NF-kappaB pathway, only NFKB1 showed a statistically significant association with NHL (P = 0.049), and one NFKB1 tagSNP (rs4648022) was associated with NHL risk overall (ordinal OR, 0.59; 95% CI, 0.41-0.84; Ptrend = 0.0037) and for each of the common subtypes. In conclusion, we provide additional evidence for the role of genetic variation in TNF and LTA SNPs and haplotypes with risk of NHL and also provide some of the first preliminary evidence for an association of genetic variation in NFKB1, a downstream target of TNF signaling, with risk of NHL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18990758      PMCID: PMC2735864          DOI: 10.1158/1055-9965.EPI-08-0536

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  28 in total

1.  Inference of population structure using multilocus genotype data.

Authors:  J K Pritchard; M Stephens; P Donnelly
Journal:  Genetics       Date:  2000-06       Impact factor: 4.562

2.  Score tests for association between traits and haplotypes when linkage phase is ambiguous.

Authors:  Daniel J Schaid; Charles M Rowland; David E Tines; Robert M Jacobson; Gregory A Poland
Journal:  Am J Hum Genet       Date:  2001-12-27       Impact factor: 11.025

3.  Trend tests for case-control studies of genetic markers: power, sample size and robustness.

Authors:  B Freidlin; G Zheng; Z Li; J L Gastwirth
Journal:  Hum Hered       Date:  2002       Impact factor: 0.444

Review 4.  The two NF-kappaB activation pathways and their role in innate and adaptive immunity.

Authors:  Giuseppina Bonizzi; Michael Karin
Journal:  Trends Immunol       Date:  2004-06       Impact factor: 16.687

Review 5.  Is there a future for TNF promoter polymorphisms?

Authors:  J-P Bayley; T H M Ottenhoff; C L Verweij
Journal:  Genes Immun       Date:  2004-08       Impact factor: 2.676

6.  From genotypes to genes: doubling the sample size.

Authors:  P D Sasieni
Journal:  Biometrics       Date:  1997-12       Impact factor: 2.571

7.  A functional TNFRSF5 gene variant is associated with risk of lymphoma.

Authors:  Christine F Skibola; Alexandra Nieters; Paige M Bracci; John D Curry; Luz Agana; Danica R Skibola; Alan Hubbard; Nikolaus Becker; Martyn T Smith; Elizabeth A Holly
Journal:  Blood       Date:  2008-02-20       Impact factor: 22.113

8.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.

Authors:  A G Wilson; J A Symons; T L McDowell; H O McDevitt; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

9.  BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping.

Authors:  Arnold Oliphant; David L Barker; John R Stuelpnagel; Mark S Chee
Journal:  Biotechniques       Date:  2002-06       Impact factor: 1.993

10.  Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis.

Authors:  Amir S Karban; Toshihiko Okazaki; Carolien I M Panhuysen; Thomas Gallegos; James J Potter; Joan E Bailey-Wilson; Mark S Silverberg; Richard H Duerr; Judy H Cho; Peter K Gregersen; Yuqiong Wu; Jean-Paul Achkar; Themistocles Dassopoulos; Esteban Mezey; Theodore M Bayless; Franklin J Nouvet; Steven R Brant
Journal:  Hum Mol Genet       Date:  2003-11-12       Impact factor: 6.150

View more
  30 in total

1.  Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non-Hodgkin lymphoma.

Authors:  Xiaofeng Bi; Tongzhang Zheng; Qing Lan; Zhijian Xu; Yingtai Chen; Gongjian Zhu; Francine Foss; Christopher Kim; Min Dai; Ping Zhao; Theodore Holford; Brian Leaderer; Peter Boyle; Qian Deng; Stephen J Chanock; Nathaniel Rothman; Yawei Zhang
Journal:  Am J Hematol       Date:  2012-05-31       Impact factor: 10.047

2.  Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma.

Authors:  James R Cerhan; Zachary S Fredericksen; Alice H Wang; Thomas M Habermann; Neil E Kay; William R Macon; Julie M Cunningham; Tait D Shanafelt; Stephen M Ansell; Timothy G Call; Thomas E Witzig; Susan L Slager; Mark Liebow
Journal:  Int J Mol Epidemiol Genet       Date:  2011-04-05

Review 3.  Host genetics in follicular lymphoma.

Authors:  James R Cerhan
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-05       Impact factor: 3.020

4.  Association between tumor necrosis factor-α gene polymorphisms and diffuse large B-cell lymphoma in Chinese Han population: evidence from two center case-control study and a meta-analysis.

Authors:  Cui Yang; Wanling Wang; Youmei Zi; Xiaolin Han; Xiaoxue Qin; Jingdong Li; Honggang Ren
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

5.  Low expression of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in non-Hodgkin lymphoma and a significant correlation with β2-microglobulin.

Authors:  Dongbing Ding; Wenbin Chen; Changfu Zhang; Zhe Chen; Yanmei Jiang; Ziyi Yang; Xudong Jiang; Yunfei Zuo; Shuangyi Ren
Journal:  Med Oncol       Date:  2014-09-03       Impact factor: 3.064

6.  Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study.

Authors:  Susan M Geyer; Lindsay M Morton; Thomas M Habermann; Cristine Allmer; Scott Davis; Wendy Cozen; Richard K Severson; Charles F Lynch; Sophia S Wang; Matthew J Maurer; Patricia Hartge; James R Cerhan
Journal:  Cancer       Date:  2010-06-15       Impact factor: 6.860

7.  Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma.

Authors:  Anne J Novak; Susan L Slager; Zachary S Fredericksen; Alice H Wang; Michelle M Manske; Steven Ziesmer; Mark Liebow; William R Macon; Stacey R Dillon; Thomas E Witzig; James R Cerhan; Stephen M Ansell
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

8.  Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk.

Authors:  Meredith S Shiels; Eric A Engels; Jianxin Shi; Maria Teresa Landi; Demetrius Albanes; Nilanjan Chatterjee; Stephen J Chanock; Neil E Caporaso; Anil K Chaturvedi
Journal:  Cancer       Date:  2012-10-08       Impact factor: 6.860

9.  TNF-β +252 A>G polymorphism and susceptibility to cancer.

Authors:  Lin Yang; Rennan Feng; Guiyou Liu; Mingzhi Liao; Liangcai Zhang; Wenbo Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-03       Impact factor: 4.553

10.  A two-stage evaluation of genetic variation in immune and inflammation genes with risk of non-Hodgkin lymphoma identifies new susceptibility locus in 6p21.3 region.

Authors:  James R Cerhan; Zachary S Fredericksen; Anne J Novak; Stephen M Ansell; Neil E Kay; Mark Liebow; Ahmet Dogan; Julie M Cunningham; Alice H Wang; Thomas E Witzig; Thomas M Habermann; Yan W Asmann; Susan L Slager
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-08-21       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.